Search results
Sanaregen Vision Therapeutics has received FDA clearance to begin a first-in-human clinical trial of SVT-001, an investigational cell therapy for Familial Drusen, a rare inherited retinal disease that currently has no approved treatment.
UK researchers have discovered that passing a weak electrical current between electrodes on a person’s scalp may lead to a reduction in frequency of the visual hallucinations experienced by some people living with sight loss.
Despite the knock-on effects of the pandemic, there’s been a lot going on this year in the world of research! Here are snapshots of a few stories that have appeared in the Research News section of our website in 2022.
Several groups around the world are investigating the use of retinal transplantation in the treatment of inherited retinal diseases.
Please read our conditions of use carefully as by using the website you will be assumed to have agreed to be bound by them.
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
The cover of this edition celebrates the success of our amazing London Marathon team. Together they have raised more than £43,000.
Giving a regular monthly or quarterly donation of any amount is a wonderful way to help Retina UK support the inherited sight loss community.
The following projects were being funded by Retina UK and have recently come to an end.
Funding from Retina UK has allowed to team to explore the viability of gene therapy as a treatment for RP and related conditions, and build a pipeline of clinical trials.
